Relay Therapeutics Inc
NASDAQ:RLAY

Watchlist Manager
Relay Therapeutics Inc Logo
Relay Therapeutics Inc
NASDAQ:RLAY
Watchlist
Price: 4.16 USD -2.35% Market Closed
Market Cap: 696.3m USD
Have any thoughts about
Relay Therapeutics Inc?
Write Note

Wall Street
Price Targets

RLAY Price Targets Summary
Relay Therapeutics Inc

Wall Street analysts forecast RLAY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RLAY is 22.44 USD with a low forecast of 16.16 USD and a high forecast of 31.5 USD.

Lowest
Price Target
16.16 USD
288% Upside
Average
Price Target
22.44 USD
439% Upside
Highest
Price Target
31.5 USD
657% Upside

RLAY Last Price Targets
Relay Therapeutics Inc

The latest public price target was made on Sep 16, 2024 by Robert Burns from H.C. Wainwright , who expects RLAY stock to rise by 357% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Robert Burns
H.C. Wainwright
19 USD
Upside 357%
3 months ago
Sep 16, 2024
Relay Therapeutics (RLAY) PT Raised to $19 at H.C. Wainwright
StreetInsider
Akash Tewari
Jefferies
16 USD
Upside 285%
3 months ago
Sep 10, 2024
Relay Therapeutics upgraded to Buy from Hold at Jefferies
TheFly
Peter Lawson
Barclays
17 USD
Upside 309%
3 months ago
Sep 9, 2024
Relay Therapeutics price target raised to $17 from $14 at Barclays
TheFly
Jason Gerberry
Bank of America Securities
20 USD
Upside 381%
3 months ago
Sep 4, 2024
Relay Therapeutics (RLAY) PT Lowered to $20 at BofA Securities
StreetInsider
Peter Lawson
Barclays
15 USD
Upside 261%
7 months ago
May 10, 2024
Barclays Upgrades Relay Therapeutics (RLAY) to Overweight
StreetInsider
Matt Biegler
Oppenheimer
25 USD
Upside 501%
7 months ago
May 6, 2024
Relay Therapeutics (RLAY) PT Lowered to $25 at Oppenheimer
StreetInsider
Akash Tewari
Jefferies
12.5 USD
Upside 200%
1 year ago
Apr 20, 2023
Jefferies Upgrades Relay Therapeutics (RLAY ) to Hold
StreetInsider
Unknown Analyst
Oppenheimer
33 USD
Upside 693%
1 year ago
Feb 3, 2023
Oppenheimer Initiates Coverage On Relay Therapeutics with Outperform Rating, Announces Price Target of $33
Benzinga
Show More Price Targets
Show Less Price Targets
Robert Burns
H.C. Wainwright
Price Target 19 USD
Upside/Downside 357%
View Source
Akash Tewari
Jefferies
Price Target 16 USD
Upside/Downside 285%
View Source
Peter Lawson
Barclays
Price Target 17 USD
Upside/Downside 309%
View Source
Jason Gerberry
Bank of America Securities
Price Target 20 USD
Upside/Downside 381%
View Source
Peter Lawson
Barclays
Price Target 15 USD
Upside/Downside 261%
View Source
Matt Biegler
Oppenheimer
Price Target 25 USD
Upside/Downside 501%
View Source
Akash Tewari
Jefferies
Price Target 12.5 USD
Upside/Downside 200%
View Source
Unknown Analyst
Oppenheimer
Price Target 33 USD
Upside/Downside 693%
View Source
Show More Price Targets
Show Less Price Targets
Relay Therapeutics Inc Competitors:
Price Targets
OCC
Orthocell Ltd
56% Downside
LGND
Ligand Pharmaceuticals Inc
11% Upside
MCRB
Seres Therapeutics Inc
332% Upside
ZNTL
Zentalis Pharmaceuticals Inc
223% Upside
INSM
Insmed Inc
29% Upside
6855
Ascentage Pharma Group International
21% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
36% Upside
ACAD
ACADIA Pharmaceuticals Inc
52% Upside

Revenue
Forecast

Revenue Estimate
Relay Therapeutics Inc

The compound annual growth rate of Relay Therapeutics Inc's revenue for the next 4 years is -2%.

N/A
Past Growth
-2%
Estimated Growth
Estimates Accuracy
-28%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Relay Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Net Income
Forecast

Net Income Estimate
Relay Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-41%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RLAY's stock price target?
Price Target
22.44 USD

According to Wall Street analysts, the average 1-year price target for RLAY is 22.44 USD with a low forecast of 16.16 USD and a high forecast of 31.5 USD.

What is Relay Therapeutics Inc's Revenue forecast?
Projected CAGR
-2%

The compound annual growth rate of Relay Therapeutics Inc's revenue for the next 4 years is -2%.

Back to Top